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Metabolic memory — the implications
for diabetic complications
Pamięć metaboliczna — rola w patogenezie przewlekłych powikłań cukrzycy
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Abstract
Many important biochemical mechanisms are activated in the presence of high levels of glucose, which occur in diabetes. Large ran-
domised studies have established that early intensive glycaemic control reduces the risk of diabetic complications. This phenomenon has
recently been dubbed ‘metabolic memory’. It has been suggested that early glycaemia normalisation can halt the hyperglycaemia-induced
pathological processes associated with enhanced oxidative stress and glycation of cellular proteins and lipids. The phenomenon of meta-
bolic memory suggests that early aggressive treatment and strict glycaemic control could prevent chronic diabetic complications.
(Pol J Endocrinol 2010; 61 (6): 700–703)
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Streszczenie
Wiele ważnych biochemicznych mechanizmów jest aktywowanych w obecności, występującego w cukrzycy wysokiego stężenia glukozy.
W wielu randomizowanych badaniach wykazano, że wczesna intensywna kontrola glikemii redukuje ryzyko powikłań cukrzycy. To
zjawisko określa się jako „pamięć metaboliczna”. Sugeruje się, że wczesna normalizacja glikemii może zatrzymać powodowane hipergli-
kemią patologiczne procesy potęgujące stres oksydacyjny i glikację białek komórkowych i lipidów. To zjawisko metabolicznej pamięci
sugeruje, że wczesne agresywne leczenie i dokładna kontrola glikemii mogą być wykorzystane w prewencji przewlekłych powikłań
cukrzycy.  (Endokrynol Pol 2010; 61 (6): 700–703)
Słowa kluczowe: stężenie glukozy, pamięć metaboliczna, powikłania cukrzycy
Introduction
The toxic influence of glucose on different tissues (so
called glucotoxicity) has been known for a long time [1,
2]. Experiments on animal models as long ago as the
mid-1980s pointed to the phenomenon of ‘metabolic
memory’. Between 2000 and 2002, the results of clinical
trials showed that an early intensive therapy aimed at
normalising metabolic control can reduce the negative
processes in cells and minimise the risk of chronic com-
plications [3–5]. Later multicenter studies confirmed
those results [6–13].
The development of chronic complications is a re-
sult of some metabolic, hormonal, environmental or
genetic action [14]. It is well known that persistent hy-
perglycaemia is responsible for the development of the
chronic complications of a microangiopathic (retinopa-
thy, nephropathy, neuropathy) as well as a macroan-
giopathic (ischaemic heart disease, cerebral and periph-
eral vessels diseases) nature.
Under the conditions of chronic hyperglycaemia,
a non-enzymatic protein glycation, polyol pathway and
oxidative stress are being activated [15]. An increased
glucose concentration leads to the LDL particles modi-
fication which results in their endothelial toxicity.
Chronic hyperglycaemia and the related inflamma-
tory state disturbs the balance between metalloprotein-
ases and their inhibitors (MMP/TIMP) causing a patho-
logical remodelling of the vessel walls, endothelium
proliferation and arteriogenesis.
Of late, there has been discussion of the ‘hypergly-
caemic memory’, a phenomenon of the pathological
processes persistence related to the increase of oxidative
stress, glycation of proteins and cellular lipids [16–18].
Ihnat et al. [19] have presented randomised studies on
this subject. A wider discussion of this issue based on
a review of the literature has been advanced by Ceriel-
lo et al. [20] and Drzewoski et al. [21].
Previously brought up phenomena are being initi-
ated as a result of hyperglycaemia’s influence already
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at the beginning of the disease.Their memory is being
preserved despite subsequent improvement of the met-
abolic control [19, 20]. Hence the importance of thor-
ough, intensive treatment of diabetes from the moment
of its diagnosis cannot be overstated. This particular,
early period of the disease is, to a great degree, a pre-
dictor of the following chronic complications and the
fate of the patient.
Chronic hyperglycaemia triggers many processes,
e.g:
— protein kinase C and phospholipase A2 activation,
leading to an increase in arachidonic acid metabo-
lites’ production;
— an increased growth factors expression, resulting in
increased vasoconstriction;
— rise of the advanced glycation end-products (AGE),
increasing oxidative stress through their interaction
with corresponding receptors (RAGE);
— glycation and oxidation of LDL;
— enhancement in expression of the nuclear transcrip-
tion factor NFkb, adhesion molecules’ concentration
rise, decrease in NO bioavailability, increase of IL-6,
TNF-a and other cytokines;
— protein kinase C activation and a rise in DAG (dia-
cyloglycerol) production, leading to a lowering of
the NADPH pool and generation of NO.
It is believed that after reaching a certain critical point
of some disturbances (like AGE accumulation) the ac-
celeration of retrograde changes in the cell still progress-
es, despite having acquired a good glycaemia control.
It has been suggested that a long-lasting good metabol-
ic control, established as soon as glucose intolerance
appears, may inhibit the development of chronic com-
plications even if subsequently the control worsens. The
‘memory’ existence awareness seems to be particularly
important in children and young adults, in whom on-
set of the disease is usually so evident that the diagno-
sis is quickly established and treatment is introduced
relatively fast. Therefore these patients stand a good
chance of a reduction in marked chronic complications.
On the other hand, older patients with diabetes type 2
are sometimes left undiagnosed and untreated for many
months, sometimes even years. In this group, the level
of hyperglycaemia is usually not as high as in type 1, so
it can often be overlooked. Unfortunately, all chronic
hyperglycaemic states lead to increased nonenzymatic
glycation and oxidative stress, and the subsequent de-
velopment of chronic complications.
Nonenzymatic protein glycation
Hyperglycaemia plays a crucial role in the pathomech-
anism of diabetic angiopathy. Its destructive influence
can take place through the activation of variable meta-
bolic pathways. A nonenzymatic protein glycation is one
of them. It is a nonezymatic binding of carbohydrates
with the rich in free amino groups particles of protein.
The early stages of glycation are reversible, but the pro-
cess results in the emergence of advanced glycation end-
products (AGE) [22, 23]. These compounds form a het-
erogenic group that derives from a nonenzymatic re-
duction of carbohydrates with the contribution of the
free amino groups, lipids and nucleic acids. AGEs have
specific membrane receptors on certain types of cells.
The nonenzymatic protein glycation pathway is an
important mechanism, through which hyperglycaemia
damages endothelial cells. Endothelial dysfunction may
play a significant role in the development of diabetic
angiopathy. On the surface of endothelial cells, specific
types of receptors are found (RAGE — advanced glyca-
tion end-products receptor). RAGE binds the advanced
glycation end-products [24]. This connection causes an
increase in oxidative stress, rise in the production of
reactive oxygen species, cytokines (TNF-a, IL-1), growth
factors (IGF-1, TGFb), adhesion molecules and the acti-
vation of the transcription nuclear factor kappa-light-
chain-enhancer of activated b-cells (NF-kb). Plenty of
studies point to the essential role AGE plays as a medi-
ator in the pathogenesis of diabetes and its complica-
tions [25]. The glycation process can affect genetic ma-
terial as well, leading to changes in gene expression.
The activation of the polyol pathway
In the circumstances of glucose increase in the extracel-
lular space, a secondary glucose metabolism pathway
is being activated. Aldose reductase transforms glucose
into sorbitol, causing its accumulation. Sorbitol excess
leads to tissue swelling and damage. Chronic hyperg-
lycaemia intensifies glucose transformation via this cy-
cle, and also changes the NADH/NADPH ratio and low-
ers the concentration of reduced glutathione. The sorb-
itol increase is accompanied by a drop in the intracellu-
lar myoinositol, which takes part in the signal
transduction inside the cell and regulates the Na+/K+
ATPase activity.
Oxidative stress
Hyperglycaemia leads to cyclooxigenase activation, glu-
cose autooxidation and disturbs the function of divalent
metal ions. The free radicals (ROS) that are formed in
the process of glucose autooxidation cause lipid and AGE
oxidation, diacyloglycerol-protein kinase C pathway ac-
tivation and the increased thromboxane synthesis.
The action of free radicals contributes also to an in-
crease in endothelium permeability and escalates the
production of the secondary glycation end-products.
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ROS cause lipid peroxidation in the cellular membranes
and activate LDL oxidation, which in this way becomes
toxic for endothelium. In diabetes, an increased lipid
peroxides concentration can be seen. They cause vaso-
constriction of vessels, especially in the heart. Free rad-
icals can activate growth factors and release the parti-
cles that play a role in monocyte and platelet adhesion
to the endothelium. They can also stimulate macroph-
ages that release cytokines damaging endothelial cells.
Many experimental studies show that ROS can induce
apoptosis within the cell.
Proteoglycans metabolism disturbances
In the process of diabetic angiopathy development, the
disturbances of the proteoglycans metabolism play
a significant role. Glycosaminoglycans (GAG) have an
important part in the pathogenesis of diabetic nephr-
opathy. The proteoglycans are macromolecular com-
ponents of the extracellular matrix. They consist of
a protein core bound covalently with the glycosami-
noglycan chains of the high grade of diversity. Hy-
perglycaemia disturbs the metabolism of the pro-
teoglycan known as heparan sulfate. A deficiency of
heparan sulfate’s (HS) leads to renal glomeruli sclero-
sis and accelerates atherosclerotic changes in the ves-
sels. Moreover, GAG deficiency increases the prolifer-
ation of smooth muscle cells.
The development of the chronic
complications of diabetes
The activation of nonenzymatic protein glycation
This process leads to the glycation of the basement
membrane, collagen, serum proteins, DNA etc. The gly-
cation of mitochondrial proteins might be part of the
explanation of the ‘metabolic memory’ phenomenon.
The glycated mitochondria that overproduce free radi-
cals in a way different from the glucose level manner
can cause mitochondrial DNA (mt DNA) damage. This
leads to a further worsening of the mitochondrial state
and further reactive oxygen species production, which
damages the cell and sustains the activation of the path-
ways responsible for the chronic complications of dia-
betes [26]. Oxidative stress can change the expression
of the mitochondrial proteins.
Advanced glycation end-products (AGE) accumu-
late in the vessel walls from the onset of diabetes, and
this is what causes their damage. Endothelium func-
tions disturbances play a significant role in the early
stages of vascular lesions [27, 28]. Vascular complica-
tions affect both main parts of the vessel wall (the inter-
na and the media), including not only functional but
also structural changes.
The intensification of glucose metabolism
via the polyol pathway
The increased activity of the polyol pathway takes place
mainly in the retina, the eye pupil, peripheral nerves
and renal glomeruli, i.e. in the regions of the insulin-
dependant glucose transport. Sorbitol accumulation
triggers a chain of reactions leading to the lowering of
sodium-potassium ATPase activity, something that
causes structural and functional disturbances in the or-
gans.
Protein kinase C activation
In the cells where the expression of aldose reductase is
low or none at all, hyperglycaemia causes increased
diacyloglycerol production, which up-regulates protein
kinase C activity. The excessive activation of protein
kinase C leads to functional and structural changes in
the cells. Hyperglycaemia can have opposite effects on
protein kinase C in different cell types. For instance,
retinal pericytes which display a high expression of al-
dose reductase under the circumstances of hypergly-
caemia begin to atrophy, which causes microaneurysms
to appear. On the other hand, endothelial cells with no
enzyme at all proliferate, leading to occlusion of the
vessel’s lumen [29].
Oxidative stress increase
There is substantial evidence linking hyperglycaemia-
induced overproduction of reactive oxygen species with
increased levels of oxidative stress in diabetic patients.
The MAP-kinases’ damage under the circumstances of
hyperglycaemia may be one of the factors responsible.
Mitogen-activated kinases (MAP, MAPK) are a group
of protein serine threonine kinases which play a role in
the regulation of the answer to the external stimuli that
reaches the cell. In endothelial cells, the overproduc-
tion of ROS is sustained long after the normalisation of
the glucose level. Many processes, such as the prolon-
gation of protein kinase C-b (PKC-b) activation, accom-
pany this phenomenon. These processes influence gene
expression as well as division, differentiation, move-
ment and apoptosis of the cells.
In glucose intolerance, an overproduction of the
endogenous inhibitor of the vascular nitric oxide syn-
thase (ADMA, asymmetric dimethylarginine) can occur.
One of the reasons for ADMA increase may also be in-
hibition of the enzyme that degrades it: dimethylargin-
ine dimethylaminohydrolase (DDAH). This enzyme is
inactivated by oxidative stress. Nitric oxide (NO) plays
a crucial role in maintaining vascular homeostasis. Its
decreased bioavailability, which can be caused either by
insulin deficiency or by defective insulin sensitivity, leads
to disturbances in the structure and function of the ves-
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sels. Hyperglycaemia also induces the production of some
vasoconstrictive agents such as endothelin 1, which
through its specific receptor causes contraction of the
smooth muscle cells in the vascular wall [30].
Molecular changes in the biology of the vessel wall of
the microcirculation that develop in the presence of high-
er than physiologic glucose concentrations on the one
hand cause a change in their functions, and on the other
are responsible for the ‘hyperglycaemic memory’ phe-
nomenon. DNA damage indirectly induced by hyperg-
lycaemia leads to the maintenance of intracellular mo-
lecular structure changes, for as long as several years [31].
The mitochondrial proteins become glycated in the
period of hyperglycaemia, which causes an increase of
superoxide anion production. In this case, even when
the glycaemia returns to normal, the glycated mitochon-
dria keep on producing the superoxide anion which
thereby activates the same pathways involved in the
development of the chronic complications of diabetes.
Hence, long-lasting hyperglycaemia before the diagno-
sis of diabetes may already in this early period leave
marks in the cells of the circulatory system and target
organs, contributing to the future development of com-
plications.
If so, this would explain the fact that the chronic
complications of diabetes can appear even in patients
with currently good metabolic control. Nowadays, it is
known that to prevent chronic complications, one has
not only to maintain good metabolic control, but also
to maintain an efficient treatment from the very first
diagnosis.
The diagnostic usefulness of oxidative stress mark-
ers in children with diabetes type 1 has been reviewed
by Krzystek-Korpacka et al. [32]. The development of
the pathogenic processes related to hyperglycaemia
caused either by insulin deficit and/or insulin resistance,
can be seen in type 1 as well as in type 2 diabetes. The
results of extensive, prospective clinical studies have
been set out by Giugliano et al. [33], who stress the need
for maximal glycaemia control. ‘Metabolic memory’ has
its role in the occurrence of vascular complications in
children as well [10, 34].
Conclusions
Very early, aggressive treatment aiming to ’normalise’
glycaemic control is needed to reduce cellular reactive
species and glycation and to minimise long-term dia-
betic complications.
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